Table 2.
Differences in quality of life (SF-36 questionnaire) between study groups.
| Baseline M (SD) | P Pre-T | 25 weeks M (SD) | P 1 (a)-PT | 6 months M (SD)) | P 2 (a)-PT | 1 year M (SD) | P 3 (a)-PT | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SF-36 | IG | PG | IG | PG | IG | PG | IG | PG | ||||
| PF | 49.43 (6.90) | 51.90 (9.92) | .199 | 45.90 (5.87) | 50.53 (9.12) | .009* | 46.05 (4.61) | 49.05 (8.03) | .049* | 47.43 (5.32) | 50.68 (7.54) | .367 |
| PR | 25.17 (6.88) | 25.86 (7.35) | .661 | 22.10 (6.84) | 25.80 (6.98) | .019* | 23.85 (7.05) | 25.47 (7.09) | .067 | 24.67 (7.24) | 26.01 (7.83) | .121 |
| BP | 75.76 (7.20) | 78.43 (12.75) | .257 | 73.12 (6.08) | 78.00 (13.07) | .036* | 74.25 (6.74) | 78.65 (13.22) | .052 | 74.84 (7.04) | 77.39 (10.65) | .234 |
| GH | 67.02 (4.25) | 68.28 (6.84) | .258 | 64.40 (4.65) | 68.35 (6.39) | .048* | 66.02 (4.12) | 67.92 (6.69) | .087 | 66.72 (5.21) | 67.63 (7.02) | .321 |
| V | 60.05 (5.23) | 58.90 (6.27) | .376 | 62.73 (5.27) | 59.48 (7.73) | .046* | 60.80 (5.11) | 58.72 (7.78) | .050* | 61.34 (4.96) | 59.01 (5.74) | .201 |
| SF | 63.23 (7.12) | 63.93 (12.41) | .758 | 58.75 (6.74) | 63.50 (11.57) | .028* | 59.85 (10.93) | 63.05 (11.87) | .075 | 60.45 (8.67) | 64.45 (10.29) | .067 |
| RE | 49.18 (7.65) | 46.35 (5.69) | .065 | 45.60 (7.85) | 47.23 (5.66) | .292 | 49.65 (6.52) | 46.40 (5.96) | .053 | 48.33 (8.31) | 47.42 (7.29) | .135 |
| MH | 76.65 (11.23) | 80.60 (9.66) | .097 | 77.48 (8.73) | 81.15 (10.42) | .069 | 74.15 (12.12) | 77.80 (7.84) | .074 | 75.64 (9.86) | 79.45 (10.35) | .083 |
Values are presented as means and standard deviations (SD). IG, intervention group; PG, placebo group; Pre-T, pre-therapy; 1 (a) PT, post-therapy after 25 weeks of treatment; 2 (a) PT, post-therapy at 6 months after end of treatment; 3 (a) PT, post-therapy at 1 year after end of treatment; PF, physical function; PR, physical role; BP, body pain; GH, general health; V, vitality; SF, social function; ER, emotional role; MH, mental health. *P = .05 (95% CI).